Navigation Links
Kinex Pharmaceuticals Acquires Rights for Technology and Products from Hanmi Pharmaceuticals, in United States and European Union Territories
Date:12/19/2011

BUFFALO, N.Y., Dec. 19, 2011 /PRNewswire/ -- Kinex Pharmaceuticals, LLC and Hanmi Pharmaceutical Co., Ltd. announced today the execution of a license agreement from Hanmi Pharmaceuticals granting Kinex Pharmaceuticals exclusive rights to their Orascovery technology (which includes a non-absorbed compound that facilitates the absorption of compounds that are usually not orally bioavailable or absorbed) and their current lead products including an oral formulation of paclitaxel, which is already in Phase II clinical trials in Korea, and an oral formulation of irinotecan, which has just completed Phase I clinical trials in Korea.

The Orascovery program is one of the key platforms developed by Hanmi Pharmaceuticals. HM30181A is a P-glycoprotein pump inhibitor, (known for its effect in pumping drugs back to the gastrointestinal tract and thereby reducing drug absorption) which inhibits the pumping action of this protein and therefore, serves as an oral absorption enhancer. This compound is very potent and is largely not absorbed and therefore, exerts its effect mainly in the gastrointestinal tract.

In preclinical studies, it has been shown that the administration of this absorption enhancer together with paclitaxel enhances the oral bioavailability of paclitaxel from 1% to >40%. For irinotecan and topotecan, the oral bioavailabilities were shown to be enhanced from 8% and 11% to >40% and >50%, respectively. The composition of matter of HM30181A is covered by issued patents.

The acquisition of an oral formulation of paclitaxel is important to both Kinex and Hanmi Pharmaceuticals as the taxanes have been shown to exhibit a strong synergistic effect with KX01, an orally bioavailable dual src kinase/pretubulin inhibitor that Kinex Pharmaceuticals and Hanmi Pharmaceuticals have been collaborating to develop since April 2011.

Under the terms of the agreement, Kinex Pharmaceuticals will acquire the rights to the development and co
'/>"/>

SOURCE Kinex Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. The Board of Directors of Kinex Pharmaceuticals Appoints Dr. David Hangauer as Chief Scientific Officer
2. The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer
3. Hanmi Pharmaceuticals to Acquire the Rights for a Promising Phase II Anti-cancer Src Kinase/Pretubulin Dual Inhibitor from Kinex Pharmaceuticals, in Selected Asian Territories
4. Charles E. Lannon Was Appointed as Vice-Chairman of the Board of Directors at Kinex Pharmaceuticals
5. Pharmaceutical Industry Veteran is Appointed CMO at Kinex Pharmaceuticals
6. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
7. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
8. Valeant Pharmaceuticals Completes Acquisition of Dermik
9. Block & Leviton LLP Investigates ISTA Pharmaceuticals, Inc.s Board of Directors for Possible Breaches of Fiduciary Duty
10. Intellect Neurosciences Files Appeal in Europe in Response to Opposition Proceedings Instituted by Elan Pharmaceuticals and Wyeth/Pfizer
11. Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals Announce Multi-Year Collaboration to Accelerate Personalized Medicine Approaches for Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Based on ... market, Frost & Sullivan recognizes Ventana Medical Systems, ... with the 2014 North American Frost & Sullivan ... quality practices along with a focus on innovation ... global leader in tissue-based cancer diagnostic solutions for ...
(Date:9/30/2014)... YORK , Sept. 30, 2014  Proteomics ... according to a new report from Kalorama Information.  The ... deals had occurred in proteomics in the past ... IPOs, to agreements between private proteomic companies and ... companies with novel proteomics innovator companies.  Kalorama observed ...
(Date:9/30/2014)... Sept. 30, 2014   Decision Resources Group ... data, anemic chronic kidney disease non-dialysis (CKD-ND) patients ... (ESA) medication. In addition, one-year persistency is similar ... Other key findings from the report entitled ... of Erythropoiesis Stimulating Agents in Late Stage Chronic ...
Breaking Medicine Technology:Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. 30, 2014 ... put the brakes on motherhood. And for many young women, ... new research suggests. Women in their early 20s appear ... tough economic times. But, according to the new study, that ... 40s and beyond. The findings suggest that higher unemployment ...
(Date:9/30/2014)... "brain tsunamis" in injured patients without opening the ... thanks to pioneering research at the University of ... led by Jed Hartings, PhD, research associate professor ... College of Medicine, has shown that spreading depolarizationselectrical ... tsunami wavescan be measured by the placement of ...
(Date:9/30/2014)... 2014 (HealthDay News) -- Sleep apnea is a potential health ... to a possible culprit behind the disorder: a "fat" tongue. ... deposits are increased in the tongue of obese patients with ... of the Sleep Center at the University of Pennsylvania Medical ... which will publish the findings Oct. 1. Sleep apnea ...
(Date:9/30/2014)... stranger to the children of Tanzania. What is rare ... services, including reliable diagnosis and evidence-based treatments. There is ... in Swahili, a major language of the region. In ... and the University of Georgia (UGA) describe a culturally ... in the country and found to be effective for ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling costs ... treat Medicare patients has had no meaningful impact on ... in the Journal of Clinical Oncology published ... chemotherapy to treat colorectal and lung cancers, and did ... those drugs following the implementation of the recent Medicare ...
Breaking Medicine News(10 mins):Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 3Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Could a 'Fat Tongue' Be a Factor in Sleep Apnea? 2Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2
... food products. According to a team of University of ... on its viewers, especially university students. , "The transition ... a time for taking on many negative health behaviors ... in physical activity and fruit and vegetable consumption," said ...
... common vaginal infection may make women more susceptible to contracting ... at Chapel Hill School of Public Health researchers have found. ... more than 30,700 women from around the world, showed that ... vaginosis in women of reproductive age were more likely ...
... standardization across ... savings, IRVINE, Calif., July 31 Masimo, ... that Aurora Health Care has completed a system-wide,conversion ... health,care provider with 13 hospitals and more than ...
... support nonprofits in Portland and Seattle that improve health ... ... 31 The Regence Foundation today,announced three grants totaling $195,000 for ... Regence,Foundation is the corporate foundation of The Regence Group and was ...
... and health systems,expert Ann Lion Coleman will join ... project in August 2008. Health Systems 20/20 is ... to strengthen health,systems by using an integrated approach ... to further the use of,life-saving priority health services., ...
... July 31 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: ... Western,healthcare products and services in the People,s Republic ... its fiscal 2009 first quarter,financial results on Thursday, ... host a conference call at 8:00 am ET ...
Cached Medicine News:Health News:Watching too much TV is causing some university students to pack on the pounds 2Health News:UNC study: Common vaginal infection may increase risk of HIV infection 2Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 2Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 3Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 4Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 5Health News:Regence Foundation Announces Three Grants Totaling $195,000 2Health News:Ann Lion Coleman Joins Abt Associates to Direct USAID Health Systems 20/20 Project 2Health News:Chindex International to Report Fiscal 2009 First Quarter Financial Results 2Health News:Chindex International to Report Fiscal 2009 First Quarter Financial Results 3
... , Standby: A standby switch maintains power to ... 1 s (1 pulse/s) , Tetanus: 100 ... s) , Output Current: Adjustable from 0-70 mA ... (200-us duration) , Indicators: Battery LED (green) indicates ...
... A range of easy to use ... RDG nerve locator, peripheral nerve stimulator, and ... insulating pole, plastic hub, and pencil point ... an inexpensive, practical and easy to use ...
Based on the original MS-1 design the new MS-1B includes low battery detection, FET based output circuitry and enhanced battery compartment....
... for the delivery and monitoring of inhaled ... is a fully integrated, innovative instrument used ... therapy. The INOvent delivery system works in ... machine) to deliver a constant concentration of ...
Medicine Products: